Intra-Cellular Therapies (NASDAQ:ITCI) reported Q2 EPS of ($0.92), $0.16 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $55.6 million versus the consensus estimate of $49.08 million.
Intra-Cellular Therapies (NASDAQ:ITCI) reported Q2 EPS of ($0.92), $0.16 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $55.6 million versus the consensus estimate of $49.08 million.